News | Patient Positioning Radiation Therapy | July 16, 2018

SpaceOAR Hydrogel Now Available in Japan

Radiotherapy gel now available to the more than 86,000 men Japanese men diagnosed with prostate cancer each year

SpaceOAR Hydrogel Now Available in Japan

July 16, 2018 — Augmenix K.K. announced that SpaceOAR hydrogel, a soft, implanted absorbable gel spacer is now available to all prostate cancer radiotherapy patients in Japan through the Ministry of Health, Labour & Welfare (MHLW) national reimbursement. SpaceOAR hydrogel is clinically proven to assist in the decrease of unwanted side effects from radiotherapy treatment in patients with prostate cancer. 1,2

Throughout Japan, more than 86,000 men are diagnosed with prostate cancer every year. Many patients are successfully treated with various forms of radiotherapy. However radiation damage to the organs surrounding the prostate are known to cause long-term side effects including acute rectal pain, rectal bleeding, urinary incontinence and erectile dysfunction. SpaceOAR hydrogel creates an average of 1.3cm of space between the prostate and the rectum, which has been clinically proven to reduce radiation exposure and prevent injury to the surrounding organs.1,2

SpaceOAR hydrogel is available nationally in Japan beginning June 25th, 2018 under the Reimbursement Category: ‘200 Bio absorbable material for Radiation Therapy’.

For more information: www.spaceoar.com

References

1. Hamstra D, et al. Continued Benefit to Rectal Separation for Prostate RT: Final Results of a Phase III Trial. Int J Radiat Oncol Biol Phys; 2017 Volume 97, Issue 5, Pages 976–985.

2. Hamstra D, et al. Evaluation of sexual function on a randomized trial of a prostate rectal spacer. J Clin Oncol 35, 2017

Related Content

MIM Software Inc. Receives FDA 510(k) Clearance for Molecular Radiotherapy Dosimetry
Technology | Nuclear Imaging | January 16, 2019
MIM Software Inc. received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for molecular radiotherapy...
Electronic Brachytherapy Effective in Long-Term Study of 1,000 Early-Stage Breast Cancers
News | Brachytherapy Systems, Women's Healthcare | January 07, 2019
Breast cancer recurrence rates of patients treated with intraoperative radiation therapy (IORT) using the Xoft Axxent...
Brachytherapy Alone Superior Treatment for Intermediate-Risk Prostate Cancer
News | Brachytherapy Systems | January 04, 2019
Patient-reported outcomes (PROs) indicated a significantly different clinician and patient-reported late toxicity...
RayStation 8B Released With Machine Learning Applications for Treatment Planning
Technology | Treatment Planning | December 27, 2018
RaySearch Laboratories released RayStation 8B, the latest version of the radiation therapy treatment planning system (...
Axillary Radiotherapy and Lymph Node Surgery Yield Comparable Outcomes for Breast Cancer
News | Radiation Therapy | December 18, 2018
Early-stage breast cancer patients with cancer detected in a sentinel lymph node biopsy had comparable 10-year...
RaySearch Developing RayCommand Treatment Control System for U.K. Proton Therapy Facility
Technology | Radiation Therapy | December 10, 2018
RaySearch has decided to develop a treatment control system, RayCommand, to act as a link between its RayStation...
Mirada Medical Joins U.K. Consortium Exploring Healthcare AI
News | Artificial Intelligence | December 04, 2018
Mirada Medical, a leading global brand in medical imaging software, will form part of an artificial intelligence (AI)...
Sponsored Content | Videos | Radiation Oncology | November 30, 2018
Accuray's philosophy is to personalize treatments to exactly fit the patient.